Wei Bo Xu

US Patent:

6509347, Jan 21, 2003

Filed:

Jun 11, 2002

Appl. No.:

10/167678

Inventors:

Wei Xu - North Wales PA
Yaling Wang - Westfield NJ

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A61K 314375

US Classification:

514300, 546122

Abstract:

The present invention relates to novel crystalline forms of the integrin v3 antagonist 3-{2-oxo-3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]imidazolidin-1-yl}-3(S)-(6-methoxy-pyridin-3-yl)-propionic acid.

US Patent:

6924282, Aug 2, 2005

Filed:

Aug 14, 2002

Appl. No.:

10/218537

Inventors:

Neville J. Anthony - Hatfield PA, US
Wei Xu - North Wales PA, US
John V. Lepore - Marlboro NJ, US
Amar J. Mahajan - Piscataway NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D417/14
A61K031/541
A61P031/18

US Classification:

5142222, 544 3

Abstract:

A sodium salt of Compound A is disclosed, wherein Compound A is of formula: Compound A is an HIV integrase inhibitor useful for preventing or treating HIV infection, for delaying the onset of AIDS, and for treating AIDS.

US Patent:

20050101593, May 12, 2005

Filed:

Oct 1, 2001

Appl. No.:

10/398366

Inventors:

Robert Meissner - Schwenksville PA, US
Wei Xu - North Wales PA, US

International Classification:

A61K031/55
C07D487/02

US Classification:

514215000, 540577000

Abstract:

The phosphoric acid salt of 3-(2-methoxy-pyrimidin-5-yl)-5-oxo-9-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)-nonanoic acid is a potent antagonist of the integrin αvβ3 receptor and is useful for the prevention and/or treatment of osteoporosis and vascular restenosis, as well as conditions associated with excessive angiogenesis, such as macular degeneration, diabetic retinopathy, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth. The invention also relates to a process for the preparation of the novel salt as well as pharmaceutical compositions and methods of use.

US Patent:

20060030581, Feb 9, 2006

Filed:

Sep 16, 2003

Appl. No.:

10/527605

Inventors:

Laura DeBusi - Schwenksville PA, US
Sami Karaborni - Lansdale PA, US
Bozen Matuszewska - North Wales PA, US
Adama Procopio - Cinnaminson PA, US
Wei Xu - North Wales PA, US
Chia-Yi Yang - North Wales PA, US

International Classification:

A61K 31/4745

US Classification:

514300000

Abstract:

Disclosed are pharmaceutical compositions of an integrin αvβ3 receptor antagonist containing mannitol as the binding agent. The compositions are prepared by wet granulation or direct compression tablet formulation. These pharmaceutical formulations are useful for inhibiting bone resorption associated with osteoporosis, metastatic bone disease, hypercalcemia of malignancy, and Paget's disease.

US Patent:

20080118559, May 22, 2008

Filed:

Dec 2, 2005

Appl. No.:

11/792190

Inventors:

Maria T. Cruanes - Lansdale PA, US
Wei Xu - North Wales PA, US
Laura M. Artino - Cakhurst NJ, US
Honggang Zhu - Collegeville PA, US

International Classification:

A61K 31/519
A61K 31/513
A61K 9/20

US Classification:

424464, 5142595, 514269

Abstract:

Pharmaceutical compositions suitable for oral administration in solid dosage forms are described. The compositions comprise an effective amount of a drug compound in the form of a salt, wherein the drug salt is characterized by conversion to a less soluble form of the drug compound under certain pH conditions, and an anti-nucleating agent.

US Patent:

20120059011, Mar 8, 2012

Filed:

Jun 4, 2010

Appl. No.:

13/319718

Inventors:

Nicholas Birringer - Philadelphia PA, US
Christopher T. John - Perkiomenville PA, US
Adam Procopio - Cinnaminson NJ, US
Bhagwant Rege - Collegeville PA, US
Lawrence A. Rosen - Wayne PA, US
Sutthilug Sotthivirat - Lansdale PA, US
Wei Xu - North Wales PA, US

International Classification:

A61K 31/4439
A61K 31/513
A61P 3/10
A61K 31/4985

US Classification:

514249, 514342, 514274

Abstract:

This invention relates to pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and pioglitazone, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.

US Patent:

20210330660, Oct 28, 2021

Filed:

Dec 7, 2020

Appl. No.:

17/114169

Inventors:

Majid Mahjour - Schwenksville PA, US
Leonardo R. Allain - Lansdale PA, US
Sutthilug Sotthivirat - Lansdale PA, US
Russell G. Maus - Collegeville PA, US
Rebecca Nofsinger - Lansdale PA, US
Lisa Lupton - South San Francisco CA, US
Wei Xu - North Wales PA, US
Francis Flanagan - North Wales PA, US

International Classification:

A61K 31/4545
A61K 47/10
A61K 9/08

Abstract:

The instant invention relates to liquid pharmaceutical compositions containing CGRP receptor antagonists. The CGRP receptor antagonist liquid pharmaceutical compositions of the instant invention are alcohol-free, low volume liquid pharmaceutical compositions that can be taken without water for the treatment of migraine headache.

US Patent:

20210085612, Mar 25, 2021

Filed:

Dec 3, 2020

Appl. No.:

17/110398

Inventors:

- Rahway NJ, US
Leonardo Resende Allain - Lansdale PA, US
W. Mark Eickhoff - Lansdale PA, US
Craig B. Ikeda - Harleysville PA, US
Chad D. Brown - Quakertown PA, US
Rebecca Nofsinger - Lansdale PA, US
Melanie Marota - Lansdale PA, US
Lisa Lupton - South San Francisco CA, US
Paresh B. Patel - Langhome PA, US
Hanmi Xi - Furlong PA, US
Wei Xu - North Wales PA, US

International Classification:

A61K 9/20
A61K 31/437
A61K 31/4545

Abstract:

The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API):wherein “R” is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.